

Invictus Therapeutics Ltd – US Patent to be Granted

Sydney, New South Wales, 29 July 2026 – The directors of Invictus Therapeutics Ltd (**Invictus**) (formerly VGI Health Technology Limited (NSX:VTL)) are pleased to announce that the United States Patent and Trademarks Office (USPTO) intends to grant a patent for the 'Transmucosal Delivery of Tocotrienols' to its wholly-owned subsidiary Invictus Biotechnology Pty Ltd and has issued a Notice of Allowance dated 16 July 2026.

Previously, a US patent directed to a method of treating post exercise muscle soreness or delayed onset muscle soreness (DOMS) by transmucosal administration of a tocotrienol was granted in June 2020. Subsequently a divisional patent application was granted by the USPTO in May 2022 which extended this coverage to pharmaceutical compositions containing delta tocotrienol which have been formulated for transmucosal delivery. The present patent formally entitled 'Transmucosal Delivery of Tocotrienol' covers an improved method for the manufacture of the transmucosal formulations. Once granted, this patent will provide commercial rights in the US until 4 December 2040.

Invictus Therapeutics Ltd's CEO and Managing Director, Dr Glenn Tong said "The US is one of the highest priority markets for both our drug development program and our nutraceuticals business and we are very pleased with this further strengthening of our intellectual property rights coverage internationally." Invictus Therapeutics Ltd has corresponding patents from two families both entitled 'Transmucosal Delivery of Tocotrienol'. The first family has granted patents in the US, Canada, Japan, the European Union, Australia, New Zealand, Singapore and South Africa. The present US patent from the second family is the first to be granted with pending patent applications in other major jurisdictions such as Japan and the European Union.

This announcement was authorised for release by the Board of the Company.

For more information please contact:

Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Catrina Glover, Company Secretary
Tel: +61 (0) 402 328 200

About Invictus Therapeutics Ltd

Invictus Therapeutics Ltd (formerly VGI Health Technology Limited (NSX:VTL)) is an Australian public listed biotechnology company developing and commercialising prescription medicines and novel dietary supplements based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD), Metabolic dysfunction-Associated Steatohepatitis (MASH), pancreatic adenocarcinoma (pancreatic cancer), hyperlipidaemia, hypertension and diabetes. Invictus owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a clinical development program for prescription medicines and a product development program for evidence-based nutraceuticals.